Semaglutide vs Mazdutide
Semaglutide vs Mazdutide: GLP-1 only vs GLP-1 + glucagon dual agonist. China-approved Mazdutide vs the global standard.
The verdict
Semaglutide is the global GLP-1 standard, single-receptor, fully FDA-approved, years of real-world use. Mazdutide adds a glucagon arm on top of GLP-1, which brings a metabolic-rate boost, and it's already approved in China for obesity though not yet globally. If you want the worldwide-established option with the deepest track record, Semaglutide. Mazdutide is the more novel dual-mechanism pick, most relevant where it's actually approved and worth watching as the dual-agonist data matures.
Semaglutide is the first wave of modern weight-loss drugs, sold as Ozempic and Wegovy. Single-receptor version of Tirzepatide. Slightly less effective and slightly rougher side effects, but well-studied and widely available.
Mazdutide is a Chinese-developed GLP-1 + glucagon dual agonist, same class as Survodutide and Retatrutide. Approved in China in 2025 for obesity. The glucagon part adds a metabolic-rate bump on top of GLP-1's appetite suppression.
Which one should you pick?
Pick Semaglutide if beginners to glp-class peptides or users with insurance coverage on wegovy / ozempic.
Pick Mazdutide if users wanting a glp/glucagon agonist with cleaner side effect profile than survodutide reports or followers of chinese metabolic-drug development.
Still torn between Semaglutide and Mazdutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.
Common questions
- Can you stack Semaglutide with Mazdutide?
- Neither entry lists the other as a stack partner. Each full entry has its own stacking notes.
- What's the dose difference between Semaglutide and Mazdutide?
- Semaglutide: Start 0.25mg weekly. Titrate every 4 weeks. Common max 2.4mg.
- Mazdutide: Start 3 mg weekly. Titrate to 6-9 mg over 4-week steps based on tolerance.
- Is Semaglutide or Mazdutide FDA approved?
- Semaglutide: Approved as Ozempic (2017, type 2 diabetes), Rybelsus (2019, oral), and Wegovy (2021, obesity).
- Mazdutide: Not FDA approved. Approved in China (2025, Innovent, brand Xinermei) for obesity and type 2 diabetes. Eli Lilly holds ex-China rights (LY-3305677) and runs US development (Phase 2).
- What are the side effects of Semaglutide vs Mazdutide?
- Semaglutide: Nausea (often more than tirzepatide); Constipation; Fatigue.
- Mazdutide: Nausea; Constipation or diarrhea; Mild fatigue.
Want the latest evidence updates?
Drop your email and we'll send you the one-page checklist for vetting any peptide before you trust a vendor or a forum: what to verify, the red flags, and the questions to ask a licensed provider. No card.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.